$616 Million is the total value of GREAT POINT PARTNERS LLC's 33 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OYST | Exit | OYSTER PT PHARMA INC | $0 | – | -70,121 | -100.0% | -0.13% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -3,892,921 | -100.0% | -0.36% | – |
| CYTK | Exit | CYTOKINETICS INCput | $0 | – | -253,000 | -100.0% | -0.49% | – |
| LQDA | Exit | LIQUIDIA TECHNOLOGIES INC | $0 | – | -1,189,607 | -100.0% | -0.53% | – |
| LNTH | Exit | LANTHEUS HLDGS INC | $0 | – | -594,750 | -100.0% | -0.68% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -2,655,763 | -100.0% | -0.84% | – |
| IVA | Exit | INVENTIVA SAads | $0 | – | -999,422 | -100.0% | -1.06% | – |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -328,817 | -100.0% | -1.12% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -943,339 | -100.0% | -1.16% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -253,230 | -100.0% | -1.25% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -1,589,724 | -100.0% | -1.35% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -446,097 | -100.0% | -1.99% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -435,000 | -100.0% | -2.54% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -1,600,000 | -100.0% | -3.85% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -2,549,525 | -100.0% | -4.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.